ArticleMolecules (Basel, Switzerland)2023
Molecular Profiling, Characterization and Antimicrobial Efficacy of Silver Nanoparticles Synthesized from
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 14 citations in OpenAlex.
- A Review on the Botany, Phytochemical Constituents, Pharmacological Activities, Toxicology, and Quality Control of the Medicinal FungusMolecules (Basel, Switzerland) · 2026Review
- Metallic nanoparticles: a promising novel therapeutic tool against antimicrobial resistance and spread of superbugs.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Review
- Correction: Khan et al. Molecular Profiling, Characterization and Antimicrobial Efficacy of Silver Nanoparticles Synthesized fromMolecules (Basel, Switzerland) · 2024Article
- Phenotypic and Genotypic Characterization of Recently Isolated Multidrug-ResistantMicroorganisms · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 7 institutions in 4 countries.
Funding
Abstract
The use of natural products isolated from mushrooms against infection, cancer diseases and other oxidative-stress-related diseases is one of the cornerstones of modern medicine. Therefore, we tried to establish a combination of medicinal mushrooms and nanotechnology possibly with the field of medicine for the development of antibacterial agents against these MDR strains. The aim of the research was to understand the molecular identification, characterization and antibacterial action of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.